MARATTO

article · Scientific Reports

Comparative in vitro cytotoxicity of free curcumin and a liposomal curcumin formulation on various human cancer cell lines

2026Open accessCairo University

Abstract

Phospholipids derived from plants are promising for drug delivery applications. This study aimed to develop liposomes from cost-effective, plant-derived soy lecithin to enhance the cytotoxicity of curcumin (CUR) against a panel of human cancer cells. The optimized curcumin-loaded liposomes (CUR-Liposomes) were characterized and exhibited a nanoscale size of 105.7 nm, and a high negative zeta potential of -49.9 mV. The key finding from the in vitro cytotoxicity assay was that CUR-liposomes demonstrated significantly enhanced anticancer activity compared to free CUR, as evidenced by lower half maximal inhibitory concentration (IC50) values across all tested cancer cell lines, including multidrug-resistant MCF-7 breast adenocarcinoma (MCF-7/ADR), colon (Caco-2), lung (A549), prostate (PC3), and pancreatic (PANC-1) cancer cells. Notably, this enhanced cytotoxicity was not observed in normal Vero cells, suggesting a favorable selectivity profile. These findings demonstrate that liposomal encapsulation using plant-derived lipids is a viable strategy to improve the therapeutic efficacy and potential selectivity of CUR for cancer treatment.

Research topics

  • Curcumin's Biomedical Applications
  • Advancements in Transdermal Drug Delivery
  • Silymarin and Mushroom Poisoning

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1038/s41598-026-36607-x

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.